Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

NCT00183937 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

15

Enrollment

OTHER

Sponsor class

Stopped Sponsor stopped study early.

Conditions

Prostate Cancer

Interventions

DRUG: PS 341
DRUG: Docetaxel

Sponsor

University of Southern California

Collaborators

[object Object]